The negative correlations with key immune checkpoints such as PDCD1 and CTLA4 further indicate its role in the immune escape mechanisms of HCC, providing a rationale for integrating FAM210B status into the selection criteria for immunotherapy. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.